The results of a phase 3 trial showed that the addition of maintenance avelumab, an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, to best supportive care, prolonged OS in patients with unresectable locally advanced or mUCC who did not have disease progression with first-line chemotherapy. Here, CD274 is linked to mucoepidermoid carcinoma.